A Preliminary Study Evaluating the Safety and Efficacy of Bumetanide, an NKCC1 Inhibitor, in Patients with Drug-Resistant Epilepsy

Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology

(2017) Robert S. Fisher et al.   EPILEPSIA

ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology

(2017) Ingrid E. Scheffer et al.   EPILEPSIA

KCC2 downregulation facilitates epileptic seizures

(2017) Lulan Chen et al.   Scientific Reports

Prevalence and Incidence of Drug-Resistant Mesial Temporal Lobe Epilepsy in the United States

(2017) Ali A. Asadi-Pooya et al.   World Neurosurgery

Compromising KCC2 transporter activity enhances the development of continuous seizure activity

(2016) Matthew R. Kelley et al.   NEUROPHARMACOLOGY

The organic anion transport inhibitor probenecid increases brain concentrations of the NKCC1 inhibitor bumetanide

(2015) Kathrin Töllner et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Pilot evaluation of the population pharmacokinetics of bumetanide in term newborn infants with seizures

(2015) Vincent Jullien et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Bumetanide for the treatment of seizures in newborn babies with hypoxic ischaemic encephalopathy (NEMO): an open-label, dose finding, and feasibility phase 1/2 trial

(2015) Ronit M Pressler et al.   LANCET NEUROLOGY

Pharmacotherapeutic targeting of cation-chloride cotransporters in neonatal seizures

(2014) Martin Puskarjov et al.   EPILEPSIA

The effect of organic anion transporter 3 inhibitor probenecid on bumetanide levels in the brain: an integratedin vivomicrodialysis study in the rat

(2014) Maria D. Donovan et al.   JOURNAL OF PHARMACY AND PHARMACOLOGY

Cation-chloride cotransporters in neuronal development, plasticity and disease

(2014) Kai Kaila et al.   NATURE REVIEWS NEUROSCIENCE

Mechanisms of epileptogenesis: a convergence on neural circuit dysfunction

(2013) Ethan M. Goldberg et al.   NATURE REVIEWS NEUROSCIENCE

Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy

(2012) Sanaz Eftekhari et al.   EPILEPSIA

Structure, Function, and Modulation of GABAAReceptors

(2012) Erwin Sigel et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments

(2012) Wolfgang Löscher et al.   NEUROPHARMACOLOGY

Disease-Modifying Effects of Phenobarbital and the NKCC1 Inhibitor Bumetanide in the Pilocarpine Model of Temporal Lobe Epilepsy

(2010) C. Brandt et al.   JOURNAL OF NEUROSCIENCE

Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies

(2009) Patrick Kwan et al.   EPILEPSIA

Decreased Seizure Activity in a Human Neonate Treated With Bumetanide, an Inhibitor of the Na+-K+-2Cl- Cotransporter NKCC1

(2009) Kristopher T. Kahle et al.   JOURNAL OF CHILD NEUROLOGY

Long-term expressional changes of Na+–K+–Cl− co-transporter 1 (NKCC1) and K+–Cl− co-transporter 2 (KCC2) in CA1 region of hippocampus following lithium-pilocarpine induced status epilepticus (PISE)

(2008) Xiubin Li et al.   BRAIN RESEARCH

Roles of the cation–chloride cotransporters in neurological disease

(2008) Kristopher T Kahle et al.   Nature clinical practice. Neurology